Specialty Pharmacy

Tanios Bekaii-Saab, MD, FACP, Mayo Clinic Cancer Center, talks about key takeaways from the phase 2 ReDOS clinical trial for specialty pharmacists.

Kohei Shitara, MD, Department of Gastrointestinal Oncology of National Cancer Center Hospital East, Japan, discusses the importance of the REVERCE clinical trial for specialty pharmacists.

Prior treatment with sorafenib followed by pembrolizumab (Keytruda) shows promising progression-free survival and overall survival in patients with advanced hepatocellular carcinoma.

Cetuximab (Erbitux) with pembrolizumab (Keytruda) shows promise in patients with mCRC.

Induction therapy shows the potential to achieve disease control in patients with locally advanced pancreatic cancer.

A novel CTC assay showed up to 88% accuracy detecting precancerous and cancerous colorectal lesions.

Nivolumab (Opdivo) alone and in combination with ipilimumab (Yervoy) induced responses in patients with heavily pretreated gastrointestinal stromal tumors.

The addition of ramucirumab did not improve overall survival in patients with HER2-negative gastric cancer.

Participants in the Transform Rheumatoid Arthritis Care program could save 5% on drug spend.

Chronochemotherapy plus an p38 MAPK inhibitor may reduce the aggressiveness of glioblastoma cells.

Three genes may increase the risk of breast and ovarian cancers in patients with BRCA mutations.

Ron Lanton III, Esq., President, True North Political Solutions, discusses the significant differences between biosimilars and generic drugs.

Top news of the day from across the health care landscape.

A majority of patients with hepatitis C experience disorders outside of the liver that are related to the virus.

Children with rheumatic diseases may experience treatment variability.

A novel Mcl-1 protein inhibitor may encourage cancer cell apoptosis.

Analytical treatment interruption may not cause long-term damage to patients with HIV.

A combination VEGFR-2 inhibitor plus an anti–PD-L1 agent demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.

Cabometyx found to improve median overall survival by 2.2 months in patients with previously treated advanced hepatocellular carcinoma.

There may not be a significant survival benefit from a surgical procedure for gastric cancer.

Brandon Newman, PharmD, CSP, Program Director, Vanderbilt Specialty Pharmacy, discusses why clinical outcomes data are important for specialty pharmacies.

Median progression-free survival was 5.8 months among patients with HER2-positive gastric cancer who were treated with DS-8201.

Top news of the day from the health care landscape.

A look at last week's top stories in the world of pharmacy.

Top news of the week from Specialty Pharmacy Times.

The unemployment rate for pharmacists is only 2%, according to the US News & World Report.

Clinical trial data that leads to FDA approvals may be difficult for the general public to understand.

Pembrolizumab (Keytruda) combination therapy may improve outcomes for patients with metastatic non-small cell lung cancer.